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Abstract
Background: Osteoporosis is a silent disease caused by low bone mineral density that results in bone fractures in 
1 out of 2 women and 1 in 4 men over the age of 50. Although several treatments for osteopenia and osteoporosis are 
available, they have severe side effects and new treatments are desperately needed. Current treatments usually target 
osteoclasts and inhibit their activity or differentiation. Treatments that decrease osteoclast differentiation and activity but 
enhance osteogenesis and osteoblast activity are not available. We recently developed a peptide, CK2.3, that induces 
bone formation and increases bone mineral density as demonstrated by injection over the calvaria of 6 to 9-day-old mice 
and tail vein injection of 8-week-old mice. CK2.3 also decreased osteoclast formation and activity. However, these studies 
raise questions: does CK2.3 induce similar results in old mice and if so, what is the effective CK2.3 concentration and, is 
the bone mineral density of vertebrae of the spinal column increased as well?
Methods: CK2.3 was systematically injected into the tail vein of female 6-month old mice with various concentrations 
of CK2.3: 0.76 μg/kg, 2.3 μg/kg, or 6.9 μg/kg per mice. Mice were sacrificed one week, two weeks, and four weeks after 
the first injection. Their spines and femurs were collected and analyzed for bone formation.
Results: Femur and lumbar spine analyses found increased bone mineral density (BMD) and mineral apposition 
rate, with greater stiffness observed in femoral samples four weeks after the first injection. Histochemistry showed that 
osteoclastogenesis was suppressed in CK2.3 treated senile mice.
Conclusions: For the first time, this study showed the increase of lumbar spine BMD by CK2.3. Moreover, it showed 
that enhancement of femur BMD was accompanied by increased femur stiffness only at medium concentration of CK2.3 
four weeks after the first injection indicating the maintenance of bone’s structural integrity by CK2.3.
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Background
Bone remodeling is a dynamic process and the balance between 
osteoclast and osteoblast activity is key to the normal bone remodeling. 
Changes in this balance may cause many bone diseases, including 
osteoporosis. Age-related or senile osteoporosis is the most common 
type of osteoporosis especially in the elderly. Bone fractures are often the 
secondary complication in patients with hip fractures posing a serious 
threat to the patients. The mortality rate ranges from 10% to 40% during 
the first year after the fracture [1]. Osteoporosis affects more than 10 
million adults in the United States [2]. Treatment of osteoporosis-related 
fractures is costly [3]. Current treatments for osteoporosis include 
bisphosphonates or hormone therapy; however these treatments exhibit 
some serious side effects including jaw pain, esophageal cancer, and 
stroke [4,5]. Therefore, a new treatment for osteoporosis with less severe 
side effects is needed to improve the quality of life for patients. 
Recombinant human bone morphogenetic protein 2 (rhBMP2) 
was approved by the FDA in 2002 to treat spinal fusion. Studies show 
that BMP2 enhances bone mineralization and increases bone mineral 
density of lumbar spines [6]. However, long term usage of BMP2 results 
in decreasing bone mass [7]. This negative effect of BMP2 on bone 
loss is supported by studies that show the effect of BMP2 in enhancing 
osteoclastogenesis [8-11]. Previously our lab has demonstrated that 
casein kinase 2 (CK2) acts as a regulatory protein of BMP2 signaling 
pathway through its interaction with BMP type I receptor (BMPRIa) 
[12,13]. Our studies have uncovered three potential CK2-interacting sites 
on BMPRIa: 475-479 aa (site 1), 324-328 aa (site 2), and 213-217 aa (site 
3) [13]. Blocking the interaction of CK2 and BMPRIa at site 3 showed 
increased osteoblastogenesis and mineralization [14,15]. Moreover, the 
injection of CK2.3 of 2.3 μg/kg per mice into the tail vein of 8-week 
old mice showed increased bone mineral density and the mineral 
apposition rate [14]. Primary pre-osteoclasts isolated from spleens of 
these mice showed decreased osteoclast differentiation and activity [14]. 
These studies raise the question about what concentration of CK2.3 
is necessary to induce osteogenesis and decrease osteoclastogenesis. 
Furthermore, will CK2.3 induce bone formation in older mice and if so, 
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is the bone stiffness also increased? Additionally, does CK2.3 directly 
affect osteoclasts in the femur and decrease their number? 
In this study we investigate the effects of three different 
concentrations (0.76 µg/kg, 2.3 µg/kg, and 6.9 µg/kg per mice) of CK2.3 
in 6-month-old mice. Our results show that all three concentrations 
of CK2.3 increased trabecular bone mineral density and mineral 
apposition rate. Moreover, the bone mineral density increased in the 
lumbar spine of the mice. In addition, all three concentrations of CK2.3 
showed a decreased number of osteoclasts one week and two weeks 
after the first CK2.3 injections. Interestingly, an increase in femur shaft 
stiffness was detected only with the 2.3 μg/kg per mouse (medium) 
concentration four weeks after the first CK2.3 injection. In addition, 
an increase in osteocalcin expression, an osteoblast marker, was also 
detected only with the 2.3 µg/kg concentration four weeks after the first 
CK2.3 injection. In conclusion, the results showed that not only CK2.3 




Retired breeders of female C57BL/6J mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME). At 6 months of age, female mice 
(n=6/group) were injected in the tail vein once a day for five consecutive 
days with CK2.3 at, 0.76 µg/kg (low), 2.3 µg/kg (medium), and 6.9 µg/
kg (high) per mouse, or 50µl of PBS as a vehicle control. The choice of 
low, medium, and high concentrations was based on FDA guidelines 
[16]. According to the guidelines, an accepted drug should have less 
than a twofold difference in minimum lethal dose and minimum 
effective dose values. Thus, the tested concentrations should be twofold 
less and twofold higher than the minimum effective dose value. 
However, in order to be ensure the safety of CK2.3 we used threefold 
less (low concentration) and threefold higher (high concentration) than 
the minimum effective dose (medium concentration). The choice of 
medium concentration was based on our previous publication where 
we found 2.3 µg/kg per mouse was the effective dose [14]. At one 
week, two weeks, and four weeks after the initial injection, mice were 
sacrificed, and femurs and spinal cords were isolated.
Bone mineral density
Analysis of volumetric bone mineral density (BMD) of femurs was 
measured by peripheral quantitative computed tomography (pQCT) 
[17].
Single photon absorptiometry (SPA) of mouse lumbar spine
Bone mineral density of the lumbar spine was measured by single 
photon absorptiometry (SPA), as the X-ray penetrates through the 
sample in a single photon ray and is reflected onto a detector [18]. The 
lumbar spine was X-rayed from the anterior side with a Nomad Pro 
Handheld X-ray System. The distance (20 cm) between the handheld 
X-ray and the lumbar spine remained constant after each measurement. 
Single view lateral dorsal radiographs were imaged of each lumbar 
spine on a ScanX Duo digital imaging system (Air Techniques, Melville, 
NY). Exposure time was 0.40 sec. The kilovoltage peak (kVp) was 60. 
The milliampere-second (mAs) was 2.5. The pixel intensity (PI) was 
calculated for each radiograph in ImageJ to estimate BMD.
Calculation of BMD
Two PIs (pixel intensities) of the background regions of interest 
(ROI) were measured using the “Measure” function of ImageJ. The 
average was then subtracted from the PI of the bone intensity ROI in 
order to obtain the BMD. PI is a measurement of a grey level value on a 
scale of 0 (black) to 255 (white) and has been shown to correspond with 
bone density (mineralized) or BMD in several other studies [19-21].
Three-point bending test
Femur stiffness was analyzed by a three-point bending test using 
RSA-G2 Solids Analyzer (TA Instruments, New Castle, DE). The mid-
shaft of the femur was compressed in the anterior-posterior direction 
with a lower support span of 4.5 mm and a loading rate of 0.05 mm/s. 
The instrument was set to stop when bone was fractured, or the 
compressive force reached 10N. The stiffness was defined as the slope of 
the linear region of the displacement vs. force graph.
Histology sample preparation
Left femurs were fixed in 10% neutral buffered formalin for 48h 
and decalcified in 14% EDTA for 3-4 weeks. Chemical end-points were 
tested with ammonium hydroxide/ammonium oxalate (1:1 v/v). Paraffin 
embedding and sectioning were performed by the Histochemistry 
and Tissue Processing Core at Nemours/Alfred I. duPont Hospital for 
Children (Wilmington, DE).
Right femurs were fixed using 10% neutral buffered formalin for 
24-48 hours at 4°C and embedded in methylmethacrylate (MMA) as 
previously described [14]. Once the femurs were polymerized into 
blocks, they were sectioned using a Buehler Diamond Watering Blade 
(10.2cm x 0.3mm) and sanded down.
Immunostaining
The paraffin embedded of left femur samples were immersed in two 
changes of 100% xylene to deparaffinize. Then, samples were rehydrated 
with washes of 100% ethanol, 96% ethanol, 70% ethanol for 5 min each, 
and deionized water for 30 seconds. Antigen retrieval was performed by 
incubation with testicular hyaluronidase at 37°C for 30 minutes. After 
antigen retrieval the samples were incubated with 3%BSA for one hour 
at room temperature. Then they were fluorescently labeled overnight at 
4°C with a mixture of primary antibodes goat polyclonal IgG osteocalcin 
(Santa Cruz Biotechnology, Dallas, TX) and rabit polyclonal IgG 
alkaline phosphatase (Santa Cruz Biotechnology). This was followed 
by a mixture of secondary antibodies with Alexafluor 488 donkey 
anti-goat IgG (Life Technologies, Waltham, MA) and Alexafluor 594 
chicken anti-rabbit for one hour at room temperature. All antibodies 
were diluted in a 3% BSA solution. Bisbenzimide (Sigma-Aldrich, St. 
Louis, MO) was used as a nuclear stain for ten minute incubation. The 
coverslips were mounted using Airvol, as previously described [22,23]. 
Images were taken on Zeiss Axiophot (Zeiss, Oberkochen, Germany) at 
200x total magnification and analyzed in ImageJ.
Image analysis
The images collected were analyzed in ImageJ through the “Analyze 
Particles” function. Briefly, images were converted to 8-bit, then the 
threshold was adjusted in order to create a black and white image 
to eliminate excess background fluorescent staining from the bone. 
Three regions of interest that corresponded to bone or marrow cavity 
area were selected and measured for “mean” pixel intensity of each 
bone or marrow cavity region per image. The image area was selected 
based upon bone or marrow cavity availability. Pixel intensity was 
shown to be equivalent to fluorescent staining intensity [24]; therefore 
calculating the “mean” pixel intensity would directly correspond to 
the intensity of the osteocalcin stain within either the bone or marrow 
cavity region. Once intensities were measured, mean pixel intensities 
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of each respective region (bone or marrow cavity) were calculated and 
averaged per respective concentration (PBS, Low, Medium, and High). 
Secondary control “mean” averages were subtracted from the “mean” 
averages of the samples in order to obtain an overall value that could 
be compared across the different concentrations for the osteocalcin 
staining intensity of the bone or marrow cavity.
Tartrate-resistant acid phosphatase (TRAP) assay
Sectioned samples of left femurs were deparaffinized in xylene using 
2 changes for 10 minutes each. Sections were then rehydrated with 
washes of 100% ethanol, 96% ethanol, 70% ethanol for 5 min each, and 
deionized water for 30 seconds. Samples were incubated in pre-warmed 
(37°C) TRAP staining solution (110 mM sodium acetate anhydrous / 50 
nM sodium L-tartrate dibasic dehydrate, pH 4.7-5.0, 0.27 mM naphthol 
AS-MX phosphate and 6.7 mM fast red violet LB salt) for 1h at 37°C. 
Then, samples were counterstained with 0.02% fast green for 2 minutes 
and dehydrated through deionized water, 70% ethanol, 96% ethanol, 
100% ethanol, and 2 changes of xylene, for 5 seconds each.
Once samples were dried, images of the growth plate and trabecular 
regions were taken using Zeiss Axiophot microscope in bright field 
at 100x total magnification with Nikon Digital Sight DS-Fi1 camera 
(Nikon, Tokyo, Japan). Three to four images were taken to get the 
whole growth plate region. Each purple TRAP+ spot was designated 
as an osteoclast. All of the osteoclasts in each image were counted and 
summed up (overlapping osteoclasts were excluded) to get the total 
number of osteoclasts in the growth plate. A blind count was conducted. 
The reported result was the average of blind count and non-blind count.
Mineral apposition rate (MAR) assay
New bone formation was labeled with 100 μl of Calcein green 
(12 mg/mL) two days apart as described previously [14]. MAR was 
determined as previously described [14].
Statistical data analysis
All data presented were analyzed using single factor analysis of 
variance (ANOVA), followed by Tukey-Kramer post-hoc test. All 
experiments were repeated three or more times and normalized to 
control. Error bars represent standard error of the mean (SEM).
Results
We report that CK2.3 increases trabecular BMD after 4 weeks of 
injection at a 2.3 µg/kg concentration [14]. We observed that CK2.3 
significantly increased trabecular BMD four weeks after the initial 
injection at CK2.3L (n=6, 0.56 g/cm3 ± 0.022) (p-value<0.01), CK2.3M 
(n=6, 0.65 g/cm3 ± 0.040) (p-value<0.01), and CK2.3H (n=6, 0.67 g/
cm3 ± 0.028) (p-value<0.0001) when compared to PBS control injection 
(n=6, 0.38 g/cm3 ± 0.051) (Figure 1). BMD was similar between the PBS 
control (n=6, 0.46 g/cm3 ± 0.011 and 0.45 g/cm3 ± 0.018) and CK2.3-
injected group at CK2.3L (n=6, 0.46 g/cm3 ± 0.031 and 0.41 g/cm3 ± 
0.023), CK2.3M ((n=6)0.49 g/cm3 ± 0.0087 and (n=5)0.49 g/cm3 ± 
0.039), and CK2.3H (n=6, 0.45 g/cm3 ± 0.023 and 0.49 g/cm3 ± 0.034) one 
week and two weeks after the initial injection, respectively (Figure 1).
Investigating bone formation, we observed that all CK2.3 doses had 
significantly increased MAR (p-value<0.0001) when compared to the 
PBS control (n=6, 7.75 µm/day ± 0.59) (Figure 2). It was observed that 
the increase of rate of bone formation was positively correlated with 
concentration of CK2.3. The CK2.3H (n=6, 19.17 µm/day ± 0.68) had 
the highest MAR and was significantly different from CK2.3M (n=6, 
14.32 µm/day ± 0.78) that was also significantly different from CK2.3L 
(n=6, 11.71 µm/day ± 0.64).
Furthermore, CK2.3 significantly enhanced lumbar spine BMD 
four weeks (p-value<0.0001) after the initial injection at CK2.3L (n=6, 
31.98 ± 1.81), CK2.3M (n=6, 28.39 ± 1.08), and CK2.3H (n=6, 30.36 ± 
1.11) concentration when compared to PBS control (n=6, 22.39 ± 1.03) 
(Figure 3).
Next, we examined the effect of CK2.3 dosage on osteoclast 
differentiation in the growth plate region of 6-month-old mice (Figure 4). 
Osteoclast was stained for TRAP, a marker of osteoclasts. Interestingly, 
our findings showed that osteoclast counts were significantly suppressed 
in the (distal) growth plate region at CK2.3L (n=6, 41.5 ± 4.0 and 38.7 
 
Figure 1: Injection of CK2.3 enhanced trabecular BMD four weeks after 
the first injection. CK2.3 didn’t affect trabecular BMD at earlier time points 
of one week and two weeks after the first injection at any concentration of 
injection. However, trabecular BMD increased four weeks after the initial 
injection at all concentrations of injection. Five to six mice were used per 
group of treatment at each time point. Statistically significance was performed 
by ANOVA followed by Tukey-Kramer (**and***=significant, p-value<0.01 and 
p-value<0.0001, respectively).
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± 3.7), CK2.3M ((n=6)54.2 ± 4.1 and (n=5)38.7 ± 2.4), and CK2.3H 
(n=6, 52.6 ± 4.8 and 20.5 ± 2.8) when compare to PBS control (n=6, 
76.7 ± 6.8 and 57.2 ± 4.0) one week (p-value<0.0001) and two weeks 
(p-value<0.0001), respectively, after the initial injection (Figure 4A). At 
week 4 (p-value=0.01), only CK2.3L (n=6, 35.9 ± 3.9) still exhibited 
inhibitory effect on osteoclastogenesis while CK2.3M (n=6, 43.8 ± 5.0) 
and CK2.3H (n=6, 42.9 ± 3.9) had no effect on osteoclastogenesis when 
compared to PBS control (n=6, 59.3 ± 4.3) (Figure 4A).
Interestingly when investigating the effect of CK2.3 on the stiffness 
of the femoral shaft, we observed that CK2.3 significantly increased the 
stiffness of the femoral shaft by 43.6% (p-value<0.05) in mice injected 
with CK2.3M (n=6, 158.90 N/mm ± 23.17) only four weeks after the 
initial injection relative to PBS injected group (n=6, 110.62 N/mm ± 
11.34) (Figure 5). CK2.3 didn’t have any effect in mice injected with 
CK2.3L and CK2.3H (Figure 5A & 5C, respectively).
To further investigate the effect of concentration of CK2.3 on 
osteoblastogenesis. We embedded right femurs in MMA, sectioned 
into thin slides (~5 µm), and labeled osteocalcin (green) and alkaline 
phosphatase (red), osteoblast markers. We observed a significant 
12-fold and 44-old increase in osteocalcin expression at CK2.3L 
and CK2.3M, respectively, four weeks after the first CK2.3 injection 
(p-value<0.0001) (Figure 6). Similarly, we observed a significant 1.8-
 
Figure 2: Injection of CK2.3 enhanced bone growth. MAR significantly 
increased in CK2.3 injected mice four weeks (p-value<0.0001) after the 
first injection. The graph represents the average bone growth in μm per 
day among the different concentrations. The images underneath the 
graph correspond with the above concentration, were taken at 100x total 
magnification and represent the trabecular bone region. Six mice were used 
per group of treatment. Statistically significance was performed by ANOVA 
followed by Tukey-Kramer (***=significant, p-value<0.0001).
Figure 3: CK2.3 increased lumbar spine BMD. CK2.3 significantly enhanced 
lumbar spine BMD four weeks (p-value<0.0001) after the first injection. A) 
X-ray images of lumbar spine, B) Quantitative analysis of x-ray images. 
Six mice were used per group of treatment. Statistically significance 
was performed by ANOVA followed by Tukey-Kramer (***=significant, 
p-value<0.0001).
 
Figure 4: CK2.3 suppressed osteoclastogenesis in vivo. Images of distal 
growth plate region of femur were taken. Osteoclasts were stained with TRAP 
staining assay and appeared as purple. Osteoclast number was significantly 
decreased one week (p-value<0.0001) and two weeks (p-value<0.0001) 
after the first injection at all concentrations. But only CK2.3L suppressed 
osteoclastogenesis four weeks (p-value<0.01) after the first injection. A) 
quantify number of osteoclasts in each treatment at different time points. 
B) representative images of each treatment at different time points. Five to 
six mice were used per treatment group at each time point. Arrows point to 
representative osteoclasts (not all osteoclasts were pointed out). Statistically 
significance was performed by ANOVA followed by Tukey-Kramer (** and 
***=significant, p-value<0.01 and p-value<0.0001, respectively).
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fold increase in alkaline phosphatase expression at both CK2.3L and 
C2.3H, and a peak 5.1-fold increase at CK2.3M four weeks after the first 
CK2.3 injection (p-value<0.0001) (Figure 7).
 
Figure 5: CK2.3 increased femoral shaft stiffness at medium concentration. 
CK2.3 didn’t affect femoral shaft stiffness at A) low or C) high concentration 
at all-time points. CK2.3 increased femoral shaft stiffness at B) medium 
concentration only four weeks after the initial injection (p-value<0.05). 
Five to six mice were used per group of treatment at each time point. 
Statistically significance was performed by ANOVA followed by Tukey-Kramer 
(*=significant, p-value<0.05).
 
Figure 6: CK2.3 elevated osteocalcin expression in osteoblasts situated in 
femoral bone cavities. CK2.3 elevated osteocalcin expression at CK2.3L and 
CK2.3M four weeks after the first CK2.3 injection with CK2.3M was the most 
effective concentration. MC: marrow cavity; B: bone. Six mice were used 
per group of treatment. Statistically significance was performed by ANOVA 
followed by Tukey-Kramer (***=significant, p-value<0.0001).
 
Figure 7: CK2.3 elevated alkaline phosphatase expression in osteoblasts 
situated in femoral bone cavities. CK2.3 elevated alkaline phosphatase 
expression at all concentrations four weeks after the first CK2.3 injection with 
CK2.3M was the most effective concentration. MC: marrow cavity; B: bone. Six 
mice were used per group of treatment. Statistically significance was performed 
by ANOVA followed by Tukey-Kramer (***=significant, p-value<0.0001).
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Discussion
Osteoporosis is a bone disease that affects an estimated 10 million 
adults in the US [2]. Typically, treatments for osteoporosis include 
bisphosphonates and hormone therapy. However, these drugs often 
have detrimental side effects [4,5]. Other treatments, such as rhBMP2 
therapy, focus on bone fracture healing by enhancing osteoblastogenesis 
[6]. Nevertheless, rhBMP2 also has limitations including its direct and 
indirect enhancement of osteoclastogenesis and bone resorption [8-11]. 
Our research led us to discover CK2 as a regulatory protein of BMP2 
signaling pathway [13]. The blocking of the binding of CK2 at one of 
the three potential binding sites on BMPRIa resulted in enhancing bone 
mineralization in vitro and in vivo and suppressing osteoclastogenesis 
and bone resorption in vitro [14]. In this study, we used 6-month-old 
female mice. It was reported that female mice had lower total body BMD 
and bone volume to tissue volume ratio (BV/TV) than male mice at 4 
to 20-month-old [25]. In addition, their study reported that both male 
and female mice were reported to have a decrease in total bone BMD 
and BV/TV. Furthermore, it shows that women over the age of 50 have 
4 times higher rate of osteoporosis and 2 times higher rate of osteopenia 
than men [26]. Thus, for this study female mice were chosen.
In this study for the first time, we showed the effect of CK2.3 on 
osteoclastogenesis and bone mineral density in the femur in vivo 
and the lumbar spine in vivo, respectively, at different concentrations 
of dosage. The dosage was based on a previous publication where 
female C57BL/6J mice were injected with CK2.3 (2.3µg/kg per mouse) 
[14]. Here, we wanted to study the effect of low (three times lower 
than previously injected dosage) and high (three times higher than 
previously injected dosage) concentrations of CK2.3. The effect of 
CK2.3 on trabecular BMD and lumbar spine BMD was observed after 
four weeks post initial injection at all three dosages (Figures 1-3). We 
also observed an increasing trend of BMD in response to an increase in 
CK2.3 concentration of injection. This observation was supported by 
the analyses of MAR (Figure 2).
An interesting finding of this study was the enhancement of 
femoral shaft stiffness which was only observed at CK2.3 medium 
concentration (2.3 µg/kg) four weeks after the first CK2.3 injection 
(Figure 5). Bone structural integrity is maintained via the process of 
bone remodeling [27]. Thus, disruption of bone remodeling process 
can lead to a weak structural integrity of bone. It was reported that 
strong inhibitors of osteoclast activity such as bisphosphonates 
weakened the structural integrity of bone and increased formation of 
micro-fractures [28]. Examining the osteoclastogenesis of the growth 
plate region of the femurs, we observed that the inhibitory effect of 
CK2.3 lasted up to four weeks at CK2.3 low concentration (0.76 μg/
kg per mouse) (Figure 4A). On the other hand, the inhibitory effect of 
CK2.3 increased as treatment was continued up two weeks at CK2.3 
high concentration (6.9 μg/kg) and lost its effect by week 4 of treatment 
(Figure 4A). Only at CK2.3 medium concentration, the inhibitory 
effect of CK2.3 was maintained at a same level until losing its effect at 
week 4 of treatment (Figure 4A). Investigating osteoblast formation, it 
showed that at CK2.3 medium concentration, expression of osteocalcin 
and alkaline phosphatase, markers of osteoblast, extremely increased at 
week 4 of treatment (Figure 6). These findings suggested while acting as 
a moderate inhibitor of osteoclast activity with short half-life and as a 
strong promoter of osteoblastogenesis at CK2.3 medium concentration, 
CK2.3 maintained the structural integrity of bone.
In this study, we found the lack of dose-dependent response in 
trabecular BMD (Figure 1) and lumbar spine BMD (Figure 3). On 
the other hand, dose-dependent response was observed in mineral 
apposition rate (Figure 2), osteoclastogenesis (Figure 4), femur stiffness 
(Figure 5), and osteocalcin expression (Figure 6). The lack of dose-
dependent response in BMD might due to the observation that higher 
concentration of CK2.3 caused more bone formation (Figure 2). On the 
other hand, less osteoclast formation was found at higher concentration 
of CK2.3 (Figure 4). Thus, this might have balanced out the BMD as the 
result of bone remodeling process as a whole.
Studies that were done on current treatments of osteoporosis such 
at BMP2 and PTH showed that long-term usage of these compounds 
resulted in enhancing osteoclast differentiation and bone resorption 
[7,29,30]. It could be speculated that long term treatment of osteoporosis 
using BMP2 and PTH might increase osteoclast differentiation and 
bone resorption due to the direct and indirect effects (via osteoblasts) 
on osteoclasts. However, due to the unique characteristic of CK2.3 that 
is, enhancing osteoblastogenesis while suppressing osteoclastogenesis, 
long term treatment using CK2.3, thus, does not increase osteoclast 
differentiation (Figure 4). The positive regulation of osteoclastogenesis 
by CK2 was reported [31,32]. Even though it is still unknown to what 
extent CK2 activity is inhibited by the binding of CK2.3, it is possible 
that CK2.3 suppressed osteoclast differentiation via inhibition of CK2 
activity.
It shows that male sex hormone, testosterone, also has similar effect 
on mediating osteoclastogenesis and osteoblastogenesis as female sex 
hormone, estrogen [33]. Therefore, future study on male subject should 
be performed to determine any gender disparities in bone formation 
resulted by the effect of CK2.3.
Conclusions
This study elucidated the important of the effect of CK2.3 
concentration on bone biology. At the right concentration, CK2.3 
showed to be an excellent bone promoter while maintaining the 
structural integrity of the bone. CK2.3 has tremendous potential as a 
novel therapeutic treatment for osteoporosis.
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